Tags

Type your tag names separated by a space and hit enter

The effect of melatonin in patients with fibromyalgia: a pilot study.

Abstract

The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients. Twenty-one consecutive patients with FM were included in an open 4-week-duration pilot study. Before and after treatment with melatonin 3 mg at bedtime, patients were evaluated using tender point count by palpation of 18 classic anatomical regions, pain score in four predesignated areas, pain severity on a 10 cm visual analogue scale (VAS), sleep disturbances, fatigue, depression, anxiety, and patient and physician global assessments, also by a VAS. Urine 6-sulphatoxymelatonin levels (aMT-6S) were measured in the patients and 20 age- and sex-matched controls. Nineteen patients completed the study. One patient withdrew because of migraine and another was lost to follow-up. At day 30, median values for the tender point count and severity of pain at selected points, patient and physician global assessments and VAS for sleep significantly improved with melatonin treatment. Other variables improved but did not reach statistical significance. Adverse events were mild and transient. Lower levels of aMT-6S were found in FM patients compared with normal median controls (+/-SD, 9.16 +/- 7.9 microg/24 h vs 16.8 +/- 12.8 microg/24 h) (p = 0.06). Although this is an open study, our preliminary results suggest that melatonin can be an alternative and safe treatment for patients with FM. Double-blind placebo controlled studies are needed.

Authors+Show Affiliations

,

Rheumatology Section, Instituto de Rehabilitación Psicofísica and Department of Physiology, Facultad de Medicina, Universidad de Buenos Aires, Argentina.

, , , , , ,

Source

Clinical rheumatology 19:1 2000 pg 9-13

MeSH

Administration, Oral
Adult
Aged
Anticonvulsants
Fatigue Syndrome, Chronic
Female
Fibromyalgia
Humans
Melatonin
Middle Aged
Pain
Pain Measurement
Pilot Projects
Sleep Wake Disorders
Treatment Outcome

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10752492

Citation

Citera, G, et al. "The Effect of Melatonin in Patients With Fibromyalgia: a Pilot Study." Clinical Rheumatology, vol. 19, no. 1, 2000, pp. 9-13.
Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol. 2000;19(1):9-13.
Citera, G., Arias, M. A., Maldonado-Cocco, J. A., Lázaro, M. A., Rosemffet, M. G., Brusco, L. I., ... Cardinalli, D. P. (2000). The effect of melatonin in patients with fibromyalgia: a pilot study. Clinical Rheumatology, 19(1), pp. 9-13.
Citera G, et al. The Effect of Melatonin in Patients With Fibromyalgia: a Pilot Study. Clin Rheumatol. 2000;19(1):9-13. PubMed PMID: 10752492.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of melatonin in patients with fibromyalgia: a pilot study. AU - Citera,G, AU - Arias,M A, AU - Maldonado-Cocco,J A, AU - Lázaro,M A, AU - Rosemffet,M G, AU - Brusco,L I, AU - Scheines,E J, AU - Cardinalli,D P, PY - 2000/4/7/pubmed PY - 2000/6/8/medline PY - 2000/4/7/entrez SP - 9 EP - 13 JF - Clinical rheumatology JO - Clin. Rheumatol. VL - 19 IS - 1 N2 - The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients. Twenty-one consecutive patients with FM were included in an open 4-week-duration pilot study. Before and after treatment with melatonin 3 mg at bedtime, patients were evaluated using tender point count by palpation of 18 classic anatomical regions, pain score in four predesignated areas, pain severity on a 10 cm visual analogue scale (VAS), sleep disturbances, fatigue, depression, anxiety, and patient and physician global assessments, also by a VAS. Urine 6-sulphatoxymelatonin levels (aMT-6S) were measured in the patients and 20 age- and sex-matched controls. Nineteen patients completed the study. One patient withdrew because of migraine and another was lost to follow-up. At day 30, median values for the tender point count and severity of pain at selected points, patient and physician global assessments and VAS for sleep significantly improved with melatonin treatment. Other variables improved but did not reach statistical significance. Adverse events were mild and transient. Lower levels of aMT-6S were found in FM patients compared with normal median controls (+/-SD, 9.16 +/- 7.9 microg/24 h vs 16.8 +/- 12.8 microg/24 h) (p = 0.06). Although this is an open study, our preliminary results suggest that melatonin can be an alternative and safe treatment for patients with FM. Double-blind placebo controlled studies are needed. SN - 0770-3198 UR - https://www.unboundmedicine.com/medline/citation/10752492/full_citation L2 - http://www.diseaseinfosearch.org/result/2854 DB - PRIME DP - Unbound Medicine ER -